What Happens If You Don’t Get Skin Cancer Removed?

Untreated skin cancer keeps growing, and over time it can destroy surrounding tissue, invade nerves and bone, spread to lymph nodes or distant organs, and ultimately become life-threatening. How fast and how far that damage goes depends almost entirely on which type of skin cancer you have. A basal cell carcinoma left alone for years may slowly eat through cartilage and bone without ever reaching another organ, while an untreated melanoma can send metastases to the lungs or brain within months. The story of neglected skin cancer is not one story but several, and understanding the differences matters more than any single rule of thumb.

The Type of Skin Cancer Changes Everything

Skin cancer is not a single disease. The three major types behave so differently when left untreated that lumping them together would be misleading.

Basal cell carcinoma (BCC) is the most common and, in most cases, the least dangerous. BCCs are slow-growing and rarely spread to other parts of the body. But “rarely metastasizes” is not the same as “harmless.” BCCs are locally invasive and can be deeply destructive, boring into cartilage, muscle, and bone if given enough time.¹ A BCC on the nose, ear, or near the eye can erode the structures beneath it over years, leading to disfigurement that becomes far harder to reconstruct than the original cancer would have been to remove.

Squamous cell carcinoma (SCC) sits in the middle of the risk spectrum. Most SCCs are curable when caught early, but they have a real capacity to metastasize. Tumor characteristics like location, size, and how deeply it has invaded the skin help predict which ones will turn dangerous.² SCCs on the head and neck are particularly aggressive. One published case described a 57-year-old man whose untreated facial SCC grew large enough to invade nerves and spread to parotid lymph nodes because he could not get timely treatment.³

Melanoma is the most dangerous of the common skin cancers. Its course depends on tumor thickness, whether the surface is ulcerated, the body site, and the specific subtype. About half of melanoma patients whose disease progresses first develop regional lymph node metastases. In the remaining half, the first sign of spread is either satellite or in-transit metastases (roughly 20%) or immediate distant metastases (roughly 30%), meaning the cancer jumps to far-off organs without passing through nearby lymph nodes first.⁴ That capacity for early distant spread is what makes melanoma so lethal when left alone.

Local Destruction When Cancer Keeps Growing

Even skin cancers that do not spread to distant organs can cause devastating local damage. BCC and SCC on the face and scalp can infiltrate the skull. A review of advanced cases found that nonmelanoma skin cancers can cause bone infiltration and perineural invasion, reaching the cranial cavity not by metastasizing through the bloodstream but simply by growing inward through tissue layers.⁵ By the time a cancer has invaded bone, surgical removal often means losing significant amounts of tissue, and reconstruction becomes complex. For cancers near the eye socket, ear canal, or nasal cavity, the functional losses can include vision, hearing, or the ability to breathe through the nose.

On the trunk or limbs the stakes are different but still serious. An SCC on the leg or arm that is left alone can ulcerate, become infected, and produce what clinicians call a malignant fungating wound, an open, weeping, and often foul-smelling lesion that erodes through skin into deeper tissue. These wounds bleed easily, attract bacteria, and are extremely difficult to manage once established. They represent one of the more distressing outcomes of neglected skin cancer, affecting both the person’s physical health and their psychological well-being.

Nerve Invasion and Its Consequences

One of the most insidious ways untreated skin cancer causes harm is by growing along nerves, a process called perineural invasion. SCCs on the head and neck are the main culprits. The trigeminal nerve (which provides sensation to the face) and the facial nerve (which controls facial muscles) are frequently involved because both have branches that extend close to the skin surface.⁶

Symptoms of cranial nerve involvement include facial pain, numbness or tingling in the face and tongue, drooping on one side of the face, inability to close the eyelid fully, and asymmetry of the mouth at rest. An 81-year-old man described in one case report had a moderately differentiated SCC of the left forehead that tracked along the trigeminal nerve, illustrating how aggressively cancer can infiltrate nerve tissue once it gains access.⁷ Once cancer reaches a nerve trunk and begins traveling toward the brain, treatment options narrow and outcomes worsen considerably.

How Treatment Delays Affect Survival

For melanoma, the link between delay and survival has been studied in large populations. A study using the National Cancer Database found that patients treated more than 119 days after biopsy had a higher risk of death compared to those treated within 30 days. The effect was especially pronounced in stage I melanoma, where waiting even 30 to 59 days was associated with a measurable increase in mortality risk, and the risk kept climbing with longer delays.⁸

A separate population-based analysis confirmed this pattern: for stage I melanoma, delays of three to five months were associated with worse melanoma-specific mortality, and any delay beyond one month was tied to worse overall mortality. For stage II, the threshold was slightly more forgiving but delays of six months or more still worsened cancer-specific survival.⁹ Interestingly, neither study found a significant effect of treatment timing in stage III disease, likely because at that point the cancer has already spread regionally and its behavior is driven more by tumor biology than by surgical timing.

The practical takeaway: melanoma caught early and removed promptly has an excellent prognosis. The same melanoma left for months loses some of that advantage, and the losses are not trivial. The idea that early removal makes a life-or-death difference is not modern marketing. As far back as 1844, the English surgeon Samuel Cooper wrote that the only chance for curing what he called “melanotic cancer” depended on early removal to prevent metastasis.¹⁰

Can Skin Cancer Go Away on Its Own?

Spontaneous regression does happen, but it is not something to count on. The phenomenon has been documented most often in melanoma, where it occurs far more frequently than in other cancers. Some estimates suggest that up to half of primary melanomas show at least partial spontaneous regression. However, regression of metastatic melanoma is vanishingly rare, observed in only about 0.23% of cases.¹¹

The immune system appears to drive this process. Studies comparing regressing and non-regressing skin tumors found that regressing cancers, whether melanoma, BCC, or variants of SCC, were infiltrated with a larger number of activated immune cells, specifically a type of helper T cell.¹² So the body does sometimes fight back. But “sometimes” and “partially” are doing heavy lifting in that sentence. Partial regression can leave behind residual cancer that continues growing, and even complete regression of the primary tumor does not guarantee that metastatic cells have not already seeded elsewhere. No dermatologist would advise waiting to see whether your immune system handles it.

When Doctors Do Recommend Watching Instead of Operating

There is one scenario where not immediately removing a skin cancer is a deliberate medical strategy rather than neglect: watchful waiting for low-risk BCCs in elderly or frail patients. For someone with limited life expectancy, serious comorbidities, or frailty that makes surgery risky, the slow growth of BCC may mean the cancer will never cause significant harm in their remaining years. A cohort study of 280 BCCs in 89 patients on watchful waiting concluded that this approach can be appropriate, particularly for asymptomatic nodular or superficial BCCs, so long as patients are followed regularly.¹³

A review of the literature on BCC in older adults echoed this, recommending that clinicians assess comorbidities, functional status, and frailty before deciding. For patients with low-risk BCCs and limited life expectancy, active surveillance can be a reasonable choice.¹⁴ This is not advice for a 45-year-old who just does not feel like dealing with a biopsy. It applies to a narrow population where the calculus of risks and benefits genuinely tilts toward monitoring. And it applies almost exclusively to BCC, not to SCC or melanoma, which move faster and carry higher stakes.

Why People Put Off Treatment

Understanding what happens when skin cancer goes untreated also means understanding why people end up in that situation. A study of patients with nonmelanoma skin cancers who delayed treatment found that denial was the most common reason, accounting for about 71% of delays. Denial in this context included thinking the spot would go away on its own, believing it was not important, being too busy, attempting self-treatment, or being afraid it might turn out to be something serious.¹⁵ Only about 10% of delays were due to difficulty scheduling an appointment.

Some findings were counterintuitive. Patients who had already had a prior skin cancer were actually more likely to delay, not less. So were patients dealing with major life problems and those with a history of any cancer. It seems that familiarity with cancer does not necessarily reduce avoidance; sometimes it increases it, perhaps because people have already been through treatment and dread repeating the experience.

For melanoma specifically, researchers studying patients’ decision-making found that the period between discovering a suspicious lesion and deciding to seek care involved a prolonged inner negotiation about the severity of the problem, personal and social considerations, and past interactions with the healthcare system.¹⁶ People do not just ignore a changing mole. They argue with themselves about it, sometimes for months. That internal debate is one of the most dangerous phases of the disease, because the cancer does not pause while you think it over.

What Advanced Neglected Skin Cancer Looks Like

When skin cancer is left long enough, it can break through the skin surface and form a malignant fungating wound. These are open, crater-like lesions that may bleed, ooze fluid, produce a strong odor from bacterial colonization, and cause constant pain. They are most common in breast cancer but occur with advanced skin cancers as well. Because the underlying cancer is still growing, the wound does not heal. Treatment at this stage is largely palliative, focused on controlling pain, managing infection and odor, reducing bleeding, and preserving as much quality of life as possible for the patient and their caregiver.¹⁷¹⁸

The psychological toll at this stage is enormous. Malignant wounds are visible, smell bad, require constant dressing changes, and serve as an inescapable reminder of the disease. Patients often withdraw socially, and caregivers report significant distress. This is the end-stage reality that lies at the far end of the spectrum when skin cancer goes completely unmanaged.

Higher Stakes for Immunosuppressed People

If you are taking immunosuppressive medications after an organ transplant, living with HIV, or on long-term drugs that dampen the immune system for autoimmune conditions, the calculus around untreated skin cancer shifts dramatically. The most common skin cancer in immunosuppressed patients is SCC, and in this population it tends to present with more aggressive features and a greater rate of metastasis than in people with healthy immune systems.¹⁹ These patients also experience greater morbidity and mortality from skin cancers overall.

The reason ties back to the immune system’s role in keeping skin cancers in check. As the regression research mentioned earlier showed, immune cells actively surveil and sometimes destroy skin cancer cells. When that surveillance is weakened by medication or disease, cancers grow faster, recur more often, and spread more readily. For immunosuppressed people, even a “low-risk” skin cancer warrants prompt attention, and the watchful waiting approach used for elderly patients with BCC is generally not appropriate.

Rarer Skin Cancers and the Importance of Diagnosis

Most skin cancers fall into the BCC, SCC, or melanoma categories, but rarer types exist and can be even more dangerous when left untreated. Merkel cell carcinoma is an uncommon, aggressive cancer that tends to recur locally and spread. In one surgical series, patients who experienced locoregional recurrence had a grim outlook: roughly two-thirds subsequently died of the disease.²⁰ Other uncommon types include dermatofibrosarcoma protuberans, sebaceous carcinoma, and various adnexal tumors. Each behaves differently, but the shared lesson is that accurate diagnosis matters. A bump you assume is a harmless cyst could turn out to be something else entirely. One case report described a metastatic SCC on a man’s temple that had masqueraded as a cyst for a prolonged period, growing and spreading while repeated cryotherapy was applied to a different spot on his ear.²

This is why a biopsy is so central to management. Without knowing exactly what you are dealing with, you cannot make an informed decision about how urgently it needs to come off. A pearly bump on the nose that turns out to be a superficial BCC may allow a few weeks of scheduling flexibility. A rapidly growing nodule that turns out to be a Merkel cell carcinoma does not. The worst outcomes from neglected skin cancer often trace back not to a conscious choice to ignore the problem but to a wrong assumption about what the problem was.

The Recurrence-to-Metastasis Pipeline in Squamous Cell Carcinoma

For SCC specifically, there is an important pattern worth knowing about. Among patients who experience a local recurrence, more than half go on to develop metastasis. And in the vast majority of those cases, the local recurrence comes first or happens at the same time as the metastatic spread.²¹ This means that if an SCC was previously treated but comes back in the same spot, it is not just a minor annoyance. A recurrence is a strong warning signal that the cancer may already be moving elsewhere or is about to. Treating a recurrence urgently can interrupt that pipeline. Ignoring it because “they already removed it once” is one of the more dangerous assumptions a person can make.